RA'ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW), in partnership with Ennocure MedTech Ltd., has announced promising results from an in vitro study of a new bio-electronic treatment aimed at preventing bloodstream infections for patients in intensive care. The study, conducted at the Hebrew University of Jerusalem, demonstrated a significant reduction in bacterial growth following the application of the technology.
The innovative treatment utilizes electrical pulses to inhibit bacterial proliferation, which could offer an alternative to traditional antiseptic and disinfectant agents. The in vitro results showed a 75% reduction in bacterial growth 4 hours after treatment and a complete 100% reduction within 24 hours. This approach is believed to potentially mitigate certain side effects associated with standard care solutions, including allergies and bacterial resistance.
Inspira Technologies intends to incorporate this bio-electronic physical stimulation technology into its INSPIRA ART, a system designed to augment respiration and potentially allow patients to remain awake during treatment, reducing the need for mechanical ventilation.
Dagi-Ben Noon, CEO of Inspira, has expressed optimism about the integration of their blood oxygenation technology with Ennocure's infection prevention solutions, potentially enhancing the benefits of INSPIRA ART. Dr. Manuela Hod, CEO of Ennocure, also voiced confidence in the technology's applicability in combating life-threatening infections.
The next step in the collaboration between Inspira and Ennocure will involve ex vivo model testing to further evaluate the treatment's efficacy before proceeding to the first prospective human trials.
Inspira Technologies is known for its development of Augmented Respiration Technology, which has not yet been tested or used in humans and is awaiting regulatory approval. Ennocure is a pioneering bio-electronic wound dressing technology that not only prevents bacterial infections but also allows for remote wound monitoring and infection alerts through AI-driven therapy.
The information provided is based on a press release statement from Inspira Technologies.
InvestingPro Insights
Inspira Technologies (NASDAQ:IINN) has been making headlines with its innovative medical technologies, and investors have been taking note of its financial metrics. As of the last twelve months ending in Q4 2023, Inspira Technologies holds a market capitalization of $33.55 million. Despite the company's cutting-edge developments, it's important to note that Inspira is not yet profitable, with an operating income of around -$12.13 million and a return on assets standing at -88.6% for the same period. The Price / Book ratio is relatively high at 5.85, indicating that the stock is trading at a premium compared to the company's book value.
On the performance front, Inspira's stock price has experienced significant volatility but also strong returns, with a 109.68% price total return over the last three months and a 52.34% return over the last year. This could reflect investor optimism about the company's potential in the medical technology space. However, it's crucial for potential investors to consider the company's cash burn rate, as indicated by the InvestingPro Tips, which highlight that Inspira is quickly burning through cash despite holding more cash than debt on its balance sheet.
For those looking to delve deeper into the financials and future prospects of Inspira Technologies, there are additional InvestingPro Tips available that could provide further insight into the company's operations and stock performance. With the use of the coupon code PRONEWS24, interested readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable insights. Currently, there are 11 additional tips listed on InvestingPro that could help investors make more informed decisions regarding Inspira Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.